Akeso Begins Phase II Trial of Bispecific ADC in Breast Cancer
Hong Kong, China, August 9, 2026 Akeso, Inc. has announced the first patient dosing in a Phase II clinical...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Hong Kong, China, August 9, 2026 Akeso, Inc. has announced the first patient dosing in a Phase II clinical...
Chicago, Illinois, USA, August 10, 2026 Beltone has announced Beltone Illuminateâ„¢, a new family of premium hearing aids designed...
